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Background: Ankyrin repeat domain 12 (ANKRD12), is encoding a 224 kDa nuclear protein and most conserved at
its N-terminal ankyrin repeats region and the C-terminal co-activator interacting domain. The aim of this study was
to investigate the ANKRD12 mRNA expression in colorectal cancer (CRC) tumor tissues and the normal adjacent
mucosa and its potential relevance to clinicopathological characteristics and prognosis.
Methods: Surgical specimens of tumor tissues (n = 68) and adjacent normal mucosa (n = 51) were obtained from
CRC patients. The ANKRD12 mRNA expression was measured by quantitative real time reverse transcriptase
polymerase chain reaction. The relationship between ANKRD12 mRNA expression and clinicopathological features
was analyzed by appropriate statistics. Kaplan–Meier analysis and Cox proportional hazards regression models were
used to investigate the correlation between ANKRD12 expression and prognosis of CRC patients.
Results: The relative mRNA expression of ANKRD12 were significantly lower in CRC tumor tissues than in the
normal adjacent mucosa (P < 0.001), and the cases with low ANKRD12 expression showed a higher frequency of
liver metastasis (P = 0.015). Kaplan–Meier analysis indicated that patients (CRC without liver metastasis) with low
ANKRD12 expression had poor overall survival (P = 0.041). Multivariate analysis showed that low ANKRD12
expression was an independent predictor of overall survival.
Conclusion: This study revealed that ANKRD12 mRNA were down regulated in CRC tumor tissues and low
ANKRD12 expression was correlated with liver metastasis and poor survival of CRC patients.
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Colorectal cancer (CRC) is one of the leading causes of
cancer mortality in the world. An estimated 143,460 new
cases of CRC occurred in 2012 and 51,690 people have
died from CRC during the same year [1]. In China, the
incidence of CRC has been increasing continually in the
most recent years. Although we have made considerable
advances in diagnosis and adjuvant therapy of CRC, the
overall survival rate of CRC patients has not been im-
proved markedly. Therefore, there is an urgent need for
better understanding of CRC pathogenesis which may
lead to more effective treatment strategies.* Correspondence: zhengshu@zju.edu.cn
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reproduction in any medium, provided the orAnkyrin repeats-containing cofactor (ANCO) proteins
contain both ankyrin repeat and transcriptional repres-
sion/activation domains [2-4], including cyclin-dependent
kinase inhibitors, transcription factors and cytoskeleton
organizers [5]. These proteins were first identified in two
yeast cell-cycle regulators, Swi6P and CDC10P, and in the
Notch and LIN-12 development regulators [6]. ANCO
proteins can inhibit the transcriptional activity of nuclear
receptors through the recruitment of histone deacetylases
(HDACs) [2]. Ankyrin repeat domain 11 (ANKRD11), also
called ANCO-1, is a member of the ankyrin repeats-
containing cofactor family. ANKRD11 was identified from
a yeast two-hybrid screen as a ras-related C3 botulinum
toxin substrate 3(RAC3)-interacting protein [2], and was
thought to recruit HDACs to the p160 co-activator to
repress transcriptional activation by nuclear receptors [7].
The N-terminal domain of the ANKRD11 was also
reported as a nasopharyngeal carcinoma-susceptibilityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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isolated as a tumor antigen present in childhood medullo-
blastoma [8]. The ANKRD11 gene locus is located within
the 16q24.3 breast cancer loss of heterozygosity (LOH) re-
gion [9]. LOH of chromosome 16q of breast cancer results
in the simultaneous loss or reduction in activity of several
tumor suppressor genes, and this contributes to the early
stages of tumorigenesis. Recently research also showed
that ANKRD11 was a p53 coactivator and involved in a
regulatory feedback loop with p53 in breast cancer [10].
All of these showed ANKRD11 is a putative tumour-
suppressor gene.
Ankyrin repeat domain 12 (ANKRD12), also called
ANCO-2, is encoding a 224 kDa nuclear protein and most
conserved at its N-terminal ankyrin repeats region and
the C-terminal co-activator-interacting domain [7]. The
similarity between ANKRD12 and ANKRD11 is most
striking at the N-terminal and C-terminal domains (67
and 81%, respectively) [2]. ANKRD12 also interacts with
p160 coactivators in GST pull-down assay suggesting that
ANKRD12 and ANKRD11 may be functionally related [2].
However, the precise role of ANKRD12 in transcriptional
regulation and tumor process is less clear.
In our study, the mRNA expression of ANKRD12 was
measured in cancer tissue and adjacent normal mucosa
of CRC by quantitative real time reverse transcriptase
polymerase chain reaction (qRT-PCR).We studied the
correlation between the relative expression of ANKRD12
and clinicopathological features to evaluate its clinical
significance. Additionally, we assessed the influence of
ANKRD12 expression on the outcomes of CRC patients.
Materials and methods
Patient and tissue samples
Tumor samples (n = 68) and adjacent normalmucosa (n = 51)
were obtained from CRC patients undergoing primary
tumor resection at the Second Affiliated Hospital of
Zhejiang University during the period between 2001 and
2007. The ethics committee of Zhejiang University ap-
proved the study. The tissue samples were snap-frozen in
liquid nitrogen and stored at −80°C until used. Patients
were evaluated at 3-month intervals for the first year after
surgery and at 6-month intervals after. The follow-up was
standard all patients. All patients were followed up by the
Cancer Research Institute until June 2012, and the data
concerning cancer recurrence and patient survival were col-
lected. The histopathology of each specimen was reviewed on
the H&E-stained tissue section to confirm diagnosis and
tumor content at least 70% of tumor cells in the tissue sample.
Isolation of RNA and quantitative reverse transcription
PCR Analysis
Total mRNA was isolated from frozen samples using
the NucleoSpin RNA II Kit (Macherey-Nagel, GA). EachmRNA sample (5 μg) was reverse transcribed using the
RT-PCR Kit (Promega). Transcript level of ANKRD12
was determined by quantitative reverse transcription PCR
(qRT-PCR) using the Applied Biosystems StepOne Real-
Time PCR System (Applied Biosystems, Carlsbad, CA).
qRT-PCR primers were ANKRD12 5′- TTTTGCGAGTT
CATTACAGAGC -3′and 5′- AATTGTCTTGCATTAAA
GCGATC -3′, β–actin 5′-TTCCAGCCTTCCTTCCTGG
G-3′ and 5′-TTGCGCTCAGGAGGAG CAAT-3′. Hu-
man β–actin was amplified as an endogenous control.
The qRT-PCR reactions were carried out in a total volume
of 20 μl per well containing SYBR master mix reagent kit
(Applied Biosystems, Carlsbad, CA) in triplicate. The rela-
tive gene expression was calculated by the equation 2-ΔΔCT.Statistical analysis
qRT-PCR data were calculated with StepOne Software
v2.1 (Applied Biosystems, Carlsbad, CA). Measurement
data were analyzed by Student’s t-test, while categorical
data were analyzed by chi-square test. The postoperative
survival rate was analyzed with Kaplan–Meier method,
and the log-rank test was used to assess the significance
of differences between survival curves. The statistical
analyses were performed using SPSS 16.0 software (SPSS,
Chicago, IL, USA). All differences were considered statisti-
cally significant if the P value was <0.05.Results
ANKRD12 mRNA expression in colorectal cancer and
normal adjacent mucosa
By qRT-PCR, we showed that ANKRD12 expression in
cancer tissues were significantly lower ( P < 0.001) than
those in the normal adjacent mucosa (Figure 1).Relationship between ANKRD12 mRNA expression and
clinicopathological features
The mRNA expression of the ANKRD12 was catego-
rized as low or high in relation to the median value. The
experimental samples were divided into two groups [the
high ANKRD12 expression group (n = 34) and the low
ANKRD12 expression group (n = 34)] to investigate
ANKRD12 mRNA expression in association with clini-
copathologic variables (Table 1). The ANKRD12 mRNA
expression was not related to age, gender, histological
type, depth of invasion(T), lymph node metastasis,
tumor location. However, the incidence in liver metasta-
sis was significantly higher (P = 0.015) in the low expres-
sion group (14 of 34, 41.2%) than in the high expression
group (5 of 34, 14.7%), and the incidence of cancer death
was significantly higher (P = 0.015) in the low expression
group (22 of 34, 64.7%) than in the high expression
group (12 of 34, 35.3%).
Figure 1 Quantitative reverse transcription-PCR showed mRNA
expression of ANKRD12 in CRC tumor tissues (T) and adjacent
normal mucosa (N). ANKRD12 expression levels were lower in tumor
tissue than in normal adjacent mucosa (p < 0.001, Student’s t test).
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Overall survival curves were plotted according to
ANKRD12 mRNA expression by the Kaplan–Meier
method. In the study group of CRC without liver
metastasis (49 patients), the overall survival rate wasTable 1 Clinicopathologic variables and ANKRD12 mRNA
expression in 68 colorectal cancers
Variables Expression P value
ANKRD12 high ANKRD12 low
(n = 34) (n = 34)





Well, Moderate 23 24
Poor and others 11 10















n Number of patients, * <0.05.significantly lower in the patients with low ANKRD12
mRNA expression than that in those with high expres-
sion (P = 0.041; Figure 2).
Univariate analysis with Cox proportional hazards
model identified four prognostic factors: location, lymph
node metastasis, liver metastasis, and ANKRD12 expre-
ssion. The other clinicopathological features, such as age,
gender, histological type and depth of invasion were not
statistically significant prognosis factors (Table 2).
Table 3 shows the result of multivariate analysis of in
the final model, which included age, histological type,
depth of invasion, location, lymph node metastasis and
ANKRD12 expression. In this model, the variable of low
ANKRD12 expression was an independent prognostic
predictor for CRC patients (HR, 2.772; 95% CI, 1.065-
7.211; P = 0.037; Table 3). Of the patients that were
entered in the multivariate analysis, patients with liver
metastasis were excluded because the presence of liver
metastasis was a strong prognostic factor and was asso-
ciated with low expression of ANKRD12.
Discussion
Gene expression regulated by steroid/nuclear hormone
receptors (NRs) is crucial in many physiological processes.
The activity of NRs is first regulated by ligands [11], as
binding of cognate ligands triggers a conformational
change that causes receptor activation [12]. Upon ligand
binding, co-repressors are released from the receptor, and
co-activators are recruited to the activated receptor [13].
Ankyrin repeats-containing cofactor (ANCO) proteins areFigure 2 Kaplan-Meier survival curves of CRC patients without
liver metastasis according to the status of ANKRD12
expression. Patients with low ANKRD12 mRNA expression showed
significantly poorer prognosis than those with high ANKRD12 mRNA
expression (P = 0.041, log-rank test).
Table 2 Univariate analysis of clinicopathological factors
for overall survival
n Hazard ratio 95% CI P value
Age (years)
≤60 36 1
>60 32 1.811 0.905-3.624 0.093
Sex
Male 41 1
Female 27 1.077 0.544-2.134 0.831
Histological type
Well, moderate 47 1
Poor and others 21 1.627 0.813-3.256 0.169
Depth of invasion
T1,2,3 53 1
T4 15 0.691 0.300-1.589 0.385
Location
Colon 39 1
Rectum 29 1.978 1.005-3.891 0.048*
Lymph node metastasis
Absent 25 1
Present 43 2.432 1.098-5.385 0.028*
Liver metastasis
Absent 49 1
Present 19 9.764 4.590-20.768 0.000*
ANKRD12
High 34 1
Low 34 2.566 1.267-5.201 0.009*
n Number of patients, CI confidence interval, * <0.05.
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properties: they interact with both the co-activators and
the co-repressors [2].
Ankyrin repeat domain 11 (ANKRD11), also called
ANCO-1, is located within the 16q24.3 breast cancer
loss of heterozygosity (LOH) region [9] and was a p53
coactivator in breast cancer [10], implying a putative
tumour-suppressor role. Ankyrin repeat domain 12
(ANKRD12), also called ANCO-2, is highly related to
ANKRD11, especially at the ankyrin repeats and
C-terminal domain. However, the clinical significance of
ANKRD12 expression in cancer remains unclear. In theTable 3 Multivariate analysis of clinicopathological factors fo
Haz
Age (>60/≤60) 0.57
Histological type (Poor and others/ Well, Moderate) 1.44
Depth of invasion (T4/ T1,2,3) 1.47
Location (Rectum/Colon) 2.00
Lymph node metastasis (present/absent) 1.88
ANKRD12 (low/high) 2.77
CI confidence interval, * <0.05.present study, we confirmed that ANKRD12 was lower
in colorectal cancer tissues than in their normal adja-
cent mucosa and the cases whose tumors had low
ANKRD12 expression showed a higher frequency of
liver metastasis, strongly suggesting that ANKRD12
might be involved in the carcinogenesis, development
and metastasis of CRC. More importantly, we proved
that ANKRD12 expression was significantly associated
with overall survival of CRC patients. In support of this,
Kaplan–Meier analysis of overall survival showed that
patients whose tumors had lower ANKRD12 expression
tend to have a significantly worse overall survival, indi-
cating that low ANKRD12 level is a marker of poor
prognosis for CRC patients. Moreover, Cox proportional
hazards model showed that low ANKRD12 expression
was an independent prognostic predictor for CRC pa-
tients. Therefore, ANKRD12 could constitute a molecu-
lar prognostic marker for CRC patients, identifying who
are more likely to have higher risk of death and need
receive a more aggressive treatment.
The precise molecular mechanisms behind the altered
expression of ANKRD12 in colorectal cancer are un-
clear. To our knowledge, this is the first report to
describe the significance of ANKRD12 to clinical stage,
lymph node and liver metastases, and prognosis of CRC
patients. ANKRD12 binds to alteration/deficiency in ac-
tivation 3(ADA3) through its C-terminal domain and
inhibits ADA3-mediated transcriptional co-activation
on NRs [7]. ADA3 is a component of the human P/CAF
acetyltransferase complex which is thought to link co-
activators to histone acetylation and basal transcription
machinery [14]. Gene expression regulated by NRs,
therefore ANKRD12 may regulate some important gene
expression by inhibiting ADA3-mediated transcriptional
co-activation on NRs. Recently, ADA3 is also identified
as a p53-binding protein [15-17], as well as causing p53
acetylation [18]. In mammalian cells, overexpression of
ADA3 increased p53 levels [16]. P53 was identified as a
tumor suppressor protein and is the most commonly
mutated gene in human cancers [19-21]. However,
ANKRD12 has little or no effect to promote p53 activa-
tion [7]. So we speculated that the effects of ANKRD12
in tumor development or progression might, throughr overall survival (CRC without liver metastasis)
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inhibit tumor development or progression. Additional
studies to investigate the real molecular mechanisms of
altered expression of ANKRD12 in the development or
progression of CRC are essential.
Conclusions
In conclusion, we found that ANKRD12 mRNA were
downregulated in CRC tumor tissues and low ANKRD12
mRNA expression correlated with poor overall survival and
liver metastasis of CRC patients. These findings suggest
that ANKRD12 is a cancer-related gene associated with
liver metastasis and a survival predictor of CRC patients.
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